The PanTheryx Story

Humanitarian Mission.

Innovative Science.

PanTheryx was founded by Tim Starzl and his wife, Bimla in 2007. What started as a humanitarian mission, led to innovative science and a broad spectrum solution to address a top global health concern.

The Challenge

In North America and Europe, many consider diarrhea to be more of a nuisance than a large-scale health problem. On the contrary, the scope and impact of the disease worldwide is truly astounding. Diarrhea is the world’s most common illness and the second leading cause of death among children under five years of age, greater than the number of childhood deaths caused by AIDS, measles, and malaria combined (exceeded only by pneumonia).1

Tim, along with his wife Bimla, a native of Northern India, worked around the clock to formulate an unconventional solution to an intractable problem. Tim poured over reams of statistical data about pediatric diarrhea in developing countries like India, and one salient fact captured his attention: children up to six months of age evidenced a substantially lower rate of pediatric diarrhea than children from six months to one year and above. He explains:

I realized that this interesting (and basically counterintuitive) statistic must be associated with the major biological interaction between mother and child in that time period, which is breast feeding.”

Tim Starzl, PanTheryx Founder

Rather than studying traditional molecular, biologic, or pharmaceutical remedies, Tim shifted his inquiry to immunology, asking what if he could formulate an inexpensive food based therapeutic that could be administered orally to reach the gastrointestinal tract.

Above and below is based on the PanTheryx story shared in the forthcoming book An Unlikely Intervention by Thomas Washing, PanTheryx Angel Investor and Director.
source: 1. http://www.who.int/mediacentre/factsheets/fs330/en/

The Pantheryx Story

Humanitarian Mission.

Innovative Science.

PanTheryx was founded by Tim Starzl and his wife, Bimla in 2007. What started as a humanitarian mission, led to innovative science and a broad spectrum solution to address a top global health concern.

The Challenge

In North America and Europe, many consider diarrhea to be more of a nuisance than a large-scale health problem. On the contrary, the scope and impact of the disease worldwide is truly astounding. Diarrhea is the world’s most common illness and the second leading cause of death among children under five years of age, greater than the number of childhood deaths caused by AIDS, measles, and malaria combined (exceeded only by pneumonia).1

Tim, along with his wife Bimla, a native of Northern India, worked around the clock to formulate an unconventional solution to an intractable problem. Tim poured over reams of statistical data about pediatric diarrhea in developing countries like India, and one salient fact captured his attention: children up to six months of age evidenced a substantially lower rate of pediatric diarrhea than children from six months to one year and above. He explains:

I realized that this interesting (and basically counterintuitive) statistic must be associated with the major biological interaction between mother and child in that time period, which is breast feeding.”

Tim Starzl, PanTheryx Founder

Rather than studying traditional molecular, biologic, or pharmaceutical remedies, Tim shifted his inquiry to immunology, asking what if he could formulate an inexpensive food based therapeutic that could be administered orally to reach the gastrointestinal tract.

Above and below is based on the PanTheryx story shared in the forthcoming book An Unlikely Intervention by Thomas Washing, PanTheryx Angel Investor and Director.
source: 1. http://www.who.int/mediacentre/factsheets/fs330/en/

A Natural Solution – Colostrum

Where research and current treatments were falling short, a natural solution and discovery was realized.

Tim theorized that a combination of bovine colostrum and immune eggs orally administered would recreate “the effect of an immunologically active mother – exposed and reactive to virtually all the diseases that might be affecting the baby.” The product platform he created has been shown to reduce acute diarrhea episodes in young children, sometimes in a matter of hours. Since cases of acute diarrhea typically last for several days or even weeks, the potential significance of the product and the menacing scale of the problem it addressed was stunning. They had successfully developed innovative science and a broad-spectrum solution to address a top global health concern.

PanTheryx — A leading distributor of colostrum in the United States

PanTheryx —
A leading distributor of colostrum in the United States

PanTheryx has acquired the two leading producers of colostrum and related nutritional products, APS BioGroup, of Phoenix, and La Belle Associates, of Bellingham, WA. With these acquisitions, PanTheryx has become the world’s premiere producer and supplier of bovine colostrum. This enables PanTheryx to realize the full potential of their breakthrough product for pediatric global health, but also demonstrates their commitment to the future potential of colostrum. PanTheryx intends to prove-out the science behind this key ingredient, expand capacity in their world-class facility, and grow the market overall.

As a science driven company, PanTheryx has the resources and capabilities to aggressively advance research to support expanded commercial opportunities. We plan to invest heavily to unlock the full potential of colostrum.”

Mark Braman, President and CEO PanTheryx

With one commercialized product on the market and several in development, we have demonstrated the medicinal potential of nature’s first passive immunity, along with our capabilities to ensure that we can meet demand to get these products to the people that need them most, and support existing and future colostrum demand.

Our research pipeline targets serious GI-related conditions—such as C. difficile infection (CDI), leaky gut, IBS/IBD, and infectious diarrhea—where our proprietary platform is mostly likely to lead to viable therapeutics.

Learn more about our clinical trials